Search results for "HEP"

showing 10 items of 12243 documents

Mosaic-activating FGFR2 mutation in two fetuses with papillomatous pedunculated sebaceous naevus

2016

International audience; Papillomatous pedunculated sebaceous naevus (PPSN) has been described as a subtype of sebaceous naevus (SN), typically affecting the scalp and face. In contrast with Schimmelpenning syndrome, no cerebral, ocular or skeletal anomalies have hitherto been reported. We report two unrelated fetuses with PPSN, one with large pink exophytic tumours, the other with minor features but similar microscopic findings. We performed whole-exome sequencing in affected skin tissue from fetus 1, which identified a postzygotic de novo FGFR2 c.1144T>C (p.Cys382Arg) mutation in 34[middle dot]6% of reads which was absent in the parents' blood. Targeted deep sequencing of FGFR2 confirmed i…

0301 basic medicinePathologymedicine.medical_specialtypapillomatousDermatologyBiologymedicine.disease_causeDeep sequencing030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinePPSN[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologymedicineNevusMissense mutationnaevusHRASFetusMutationintegumentary systemmedicine.disease3. Good health030104 developmental biologymedicine.anatomical_structureSchimmelpenning syndromeScalp[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Guidelines are silver, but a multidisciplinary team discussion may be golden?

2018

0301 basic medicinePatient Care TeamMedical educationCarcinoma HepatocellularSilverHepatologybusiness.industryLiver NeoplasmsMultidisciplinary teamCombined Modality Therapy03 medical and health sciences030104 developmental biology0302 clinical medicineMedicineHumans030211 gastroenterology & hepatologybusinessLiver international : official journal of the International Association for the Study of the Liver
researchProduct

11 and 15-month-old infants do not compensate immediately for energy variation, and no further adjustment occurs 12 or 24 hours later

2021

International audience; Previously, we demonstrated that, in the short term, infants undercompensated for the energy from a preload given 25 min before an ad libitum meal. However, although not consistent, there is evidence in young children that caloric adjustment may occur over longer periods. We investigated the extent to which further energy adjustment occurs up to 24 h after a single meal preceded by preloads of varying energy density (ED) in infants that are 11 and 15 months old. Short-term caloric adjustment was measured in 11- and 15-month-old infants through a preload paradigm meal in the laboratory. To assess their caloric adjustment over longer periods (12 and 24 h), we used 24 h…

0301 basic medicinePediatricsmedicine.medical_specialtyAppetite controlCOMPXEnergy balanceAppetite030209 endocrinology & metabolism03 medical and health sciences0302 clinical medicineappetite controlpreload paradigmmedicineHumansChildMealsGeneral PsychologyMeal[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics030109 nutrition & dieteticsNutrition and DieteticsAppetite Regulationbusiness.industrydigestive oral and skin physiologyInfantCaloric theoryDiet RecordsPreloadChild Preschooldietary recordEnergy densityEnergy variationenergy intakecaloric adjustmentmedicine.symptomEnergy MetabolismbusinessWeight gain[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
researchProduct

Phenotypic spectrum and diagnostic pitfalls of ABCB4 deficiency depending on age of onset.

2017

Genetic variants in the adenosine triphosphate-binding cassette subfamily B member 4 (ABCB4) gene, which encodes hepatocanalicular phosphatidylcholine floppase, can lead to different phenotypes, such as progressive familial intrahepatic cholestasis (PFIC) type 3, low phospholipid-associated cholelithiasis, and intrahepatic cholestasis of pregnancy. The aim of this multicenter project was to collect information on onset and progression of this entity in different age groups and to assess the relevance of this disease for the differential diagnosis of chronic liver disease. Clinical and laboratory data of 38 patients (17 males, 21 females, from 29 families) with homozygous or (compound) heter…

0301 basic medicinePediatricsmedicine.medical_specialtyHepatologybusiness.industryProgressive familial intrahepatic cholestasisMedizinOriginal ArticlesABCB4Jaundicemedicine.diseaseChronic liver disease03 medical and health sciencesLiver disease030104 developmental biology0302 clinical medicineBiliary atresiamedicine030211 gastroenterology & hepatologyOriginal ArticleAge of onsetmedicine.symptombusinessCholestasis of pregnancyHepatology communications
researchProduct

Nutritional Wheat Amylase-Trypsin Inhibitors Promote Intestinal Inflammation via Activation of Myeloid Cells.

2016

Background & Aims Wheat amylase-trypsin inhibitors (ATIs) are nutritional activators of innate immunity, via activation of the toll-like receptor 4 (TLR4) on myeloid cells. We aimed to characterize the biologic activity of ATIs in various foods and their effect on intestinal inflammation. Methods We selected 38 different gluten-containing and gluten-free products, either unprocessed (such as wheat, rye, barley, quinoa, amaranth, soya, lentils, and rice) or processed (such as pizza, pasta, bread, and biscuits). ATIs were extracted and their biological activities determined in TLR4-responsive mouse and human cell lines. Effects of oral ATIs on intestinal inflammation were determined in health…

0301 basic medicinePharmacologyAdaptive Immunitychemistry.chemical_compoundMice0302 clinical medicineMesenteric lymph nodesMesenteryMyeloid CellsTriticumPlant ProteinsToll-like receptorDextran SulfateGastroenterologyfood and beveragesColitisIntestinesmedicine.anatomical_structureAmylases030211 gastroenterology & hepatologymedicine.symptomTrypsin InhibitorsInterferon InducersGlutensColonDuodenumInflammationIleumBiologyCell Line03 medical and health sciencesDiet Gluten-FreeIleummedicineAnimalsHumansColitisInflammationInnate immune systemHepatologymedicine.diseaseImmunity InnateMice Inbred C57BLToll-Like Receptor 4Celiac Disease030104 developmental biologyPoly I-CchemistryPolyinosinic:polycytidylic acidImmunologyLymph NodesWheat allergyGastroenterology
researchProduct

Chemoresistance and chemosensitization in cholangiocarcinoma

2017

One of the main difficulties in the management of patients with advanced cholangiocarcinoma (CCA) is their poor response to available chemotherapy. This is the result of powerful mechanisms of chemoresistance (MOC) of quite diverse nature that usually act synergistically. The problem is often worsened by altered MOC gene expression in response to pharmacological treatment. Since CCA includes a heterogeneous group of cancers their genetic signature coding for MOC genes is also diverse; however, several shared traits have been defined. Some of these characteristics are shared with other types of liver cancer, namely hepatocellular carcinoma and hepatoblastoma. An important goal in modern onco…

0301 basic medicinePharmacologybile ductschemotherapydrug delivery systems0302 clinical medicineChemosensitizationantineoplastic agentsmolecular biologyReceptorhumansreceptor protein-tyrosine kinasesmedia_commonapoptosisgene expression regulationbile duct neoplasmsDrug Resistance Multipletargeted therapiesGene Expression Regulation Neoplasticmultiplebiliary cancer; chemotherapy; liver cancer; multidrug resistance; targeted therapies; antineoplastic agents; apoptosis; bile duct neoplasms; bile ducts; cell survival; cholangiocarcinoma; drug delivery systems; drug resistance multiple; drug resistance; neoplasm; epithelial cells; gene expression regulation neoplastic; genetic therapy; humans; protein kinase inhibitors; receptor protein-tyrosine kinases; signal transduction; treatment outcome; molecular medicine; molecular biology030220 oncology & carcinogenesisHepatocellular carcinomabiliary cancerLiver cancercholangiocarcinomaTyrosine kinasesignal transductionDrugHepatoblastomamedia_common.quotation_subjectcell survivalPharmacological treatmentliver cancer03 medical and health sciencesmultidrug resistancemedicinemolecular medicinedrug resistancebusiness.industrymedicine.diseaseepithelial cellsneoplasticprotein kinase inhibitors030104 developmental biologyDrug Resistance NeoplasmCancer researchtreatment outcomebusinessneoplasmgenetic therapy
researchProduct

Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis

2017

Background and Purpose Liver fibrosis is a major cause of liver-related mortality and, so far, no effective antifibrotic drug is available. Galunisertib, a TGF-β receptor type I kinase inhibitor, is a potential candidate for the treatment of liver fibrosis. Here, we evaluated the potency of galunisertib in a human ex vivo model of liver fibrosis. Experimental Approach Antifibrotic potency and associated mechanisms were studied ex vivo, using both healthy and cirrhotic human precision-cut liver slices. Fibrosis-related parameters, both transcriptional and translational level, were assessed after treatment with galunisertib. Key Results Galunisertib showed a prominent antifibrotic potency. Ph…

0301 basic medicinePharmacologymedicine.medical_specialtyPharmacologyBiologyExtracellular matrix03 medical and health sciences030104 developmental biology0302 clinical medicineEndocrinologyMechanism of action030220 oncology & carcinogenesisInternal medicinemedicineHepatic stellate cellGalunisertibPotencymedicine.symptomSignal transductionReceptorEx vivoBritish Journal of Pharmacology
researchProduct

Niemann-Pick type C2 protein supplementation in experimental non-alcoholic fatty liver disease

2017

BACKGROUND AND AIMS: Hepatic cholesterol deposition drives inflammation and fibrosis in non-alcoholic steatohepatitis (NASH). The Niemann-Pick type C2 (NPC2) protein plays an important role in regulating intracellular cholesterol trafficking and homeostasis. We hypothesized that intravenous NPC2 supplementation reduces cholesterol accumulation, hepatic inflammation and fibrogenesis in a nutritional NASH rat model.METHODS: Rats were fed a high-fat, high-cholesterol (HFHC) diet for four weeks resulting in moderately severe NASH. Animals were treated with intravenous NPC2 or placebo twice weekly for either the last two weeks or the entire four weeks. End-points were liver/body- and spleen/body…

0301 basic medicinePhysiologyGene Expressionlcsh:MedicinePathology and Laboratory MedicineBiochemistrychemistry.chemical_compound0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFibrosisImmune PhysiologyMedicine and Health Scienceslcsh:ScienceImmune ResponseSterol Regulatory Element Binding ProteinsInnate Immune SystemMultidisciplinarybiologyLiver DiseasesReverse cholesterol transportFatty liverIntracellular Signaling Peptides and ProteinsLipidsCholesterolLiverCytokinesLiver FibrosisFemale030211 gastroenterology & hepatologylipids (amino acids peptides and proteins)Research Articlemedicine.medical_specialtyImmunologyBiological Transport ActiveGastroenterology and HepatologyCollagen Type I03 medical and health sciencesSigns and SymptomsDiagnostic MedicineInternal medicineGeneticsmedicineAnimalsRats WistarGlycoproteinsNutritionInflammationbusiness.industryCholesterollcsh:RBiology and Life Sciencesnutritional and metabolic diseasesMolecular Developmentmedicine.diseaseDietary FatsFibrosisRatsDietCollagen Type I alpha 1 ChainPPAR gammaFatty LiverDisease Models Animal030104 developmental biologyEndocrinologychemistryImmune SystemABCA1LDL receptorbiology.proteinlcsh:QSteatohepatitisCarrier ProteinsbusinessDevelopmental BiologyLipoprotein
researchProduct

Interactions between odorants and glutathione transferases in the human olfactory cleft

2020

AbstractXenobiotic metabolizing enzymes and other proteins, including odorant-binding proteins located in the nasal epithelium and mucus, participate in a series of processes modulating the concentration of odorants in the environment of olfactory receptors (ORs) and finely impact odor perception. These enzymes and transporters are thought to participate in odorant degradation or transport. Odorant biotransformation results in 1) changes in the odorant quantity up to their clearance and the termination of signaling and 2) the formation of new odorant stimuli (metabolites). Enzymes, such as cytochrome P450 and glutathione transferases (GSTs), have been proposed to participate in odorant clea…

0301 basic medicinePhysiologyOlfaction03 medical and health sciencesBehavioral NeuroscienceGSTP1chemistry.chemical_compound0302 clinical medicineOlfactory MucosaPhysiology (medical)glutathione transferasemedicine[SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]HumanshumanReceptorGSTP1odorantchemistry.chemical_classificationbiologymusculoskeletal neural and ocular physiology[SCCO.NEUR]Cognitive science/NeuroscienceCytochrome P450TransporterGlutathioneSensory Systems3. Good health030104 developmental biologymedicine.anatomical_structureEnzymeGSTA1chemistryBiochemistryOdorantsbiology.proteinOlfactory epithelium[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition030217 neurology & neurosurgerypsychological phenomena and processesolfaction
researchProduct

Nutritional Intake and the Risk for Non-Alcoholic Fatty Liver Disease (NAFLD)

2019

The prevalence of non-alcoholic fatty liver disease (NAFLD) is rising worldwide, and it is estimated that approximately one billion individuals may be afflicted with NAFLD globally [...]

0301 basic medicinePhysiologylcsh:TX341-641DiseaseGlobal Healthdigestive system03 medical and health sciences0302 clinical medicineFeeding behaviorNon-alcoholic Fatty Liver DiseaseGlobal healthMedicineHumans030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryFatty livernutritional and metabolic diseasesNon alcoholicFeeding BehaviorDietary patternmedicine.diseasedigestive system diseasesEditorialn/a030211 gastroenterology & hepatologybusinesslcsh:Nutrition. Foods and food supplyFood ScienceNutrients
researchProduct